Sticking it to KRAS: Covalent Inhibitors Enter the Clinic-Reference-Cited by-同舟云学术

Sticking it to KRAS: Covalent Inhibitors Enter the Clinic

Published:2020-01 Issue:1 Volume:37 Page:3-4
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

McCormick Frank

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference10 articles.

1. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity;Canon;Nature,2019

2. Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA;Coelho;Immunity,2017

3. The KRASG12C inhibitor, MRTX849, provides insight toward therapeutic susceptibility of KRAS mutant cancers in mouse models and patients;Hallin;Cancer Discov.,2019

4. The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors;Hansen;Nat. Struct. Mol. Biol.,2018

5. Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor;Janes;Cell,2018

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies;Signal Transduction and Targeted Therapy;2024-08-23

2. KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination;Cell Communication and Signaling;2024-06-12

3. Oridonin inhibits bladder cancer survival and immune escape by covalently targeting HK1;Phytomedicine;2024-04

4. Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors;British Journal of Cancer;2024-01-26

5. Considerations Around Structure-Based Drug Discovery for KRAS Using DOCK;Methods in Molecular Biology;2024